Myc oncogene disrupts circadian and metabolism rhythms in cancer cells

Myc is a cancer-causing gene responsible for disrupting the normal 24-hour internal rhythm and metabolic pathways in cancer cells, according to research published in Cell Metabolism (2015; doi:10.1016/j.cmet.2015.09.003).

The researchers, from the laboratory of senior author Chi Van Dang, MD, PhD, director of Abramson Cancer Center at the University of Pennsylvania in Philadelphia, found that MYC may affect circadian rhythm and metabolism by promiscuously binding to promoter regions in key genes for maintaining these daily cycles.

"Our data suggest that MYC-driven cancers have altered circadian oscillation due to upregulation in another clock protein called REV-ERBα, and that these Myc cancers may be good candidates for chronotherapy," said coauthor Brian Altman, PhD, of Abramson.

 "This work ties together the study of cell metabolism and cancer chronotherapy. If cells don't have to 'rest,' they may replicate all the time, with no breaks at all. Cancer chronotherapy is based on the concept that the right time of treatment during the day could decrease side effects to normal cells while killing cancer cells.”

“Understanding these basic mechanisms should lead to better cancer treatment strategies that reduce side effects and increase effectiveness," said coauthor Annie Hsieh, MD, also of Abramson.

The team found that MYC is a double-duty protein. In addition to its role in metabolic pathways, MYC also works directly on damping BMAL1 in its tumor-suppressor role via spurring increased REV-ERBα activity. Essentially MYC suppresses the BMAL1 suppressor.

In the current paper, knowing that MYC, a transcription factor that binds the genome through sites that are identical to the binding sites of BMAL1, the team hypothesized that aberrant MYC expression perturbs the clock by deregulating components of the circadian network in cancer cells.

They found that deregulated expression of MYC disrupts the molecular clock in cell lines by directly inducing REV-ERBα to dampen expression and oscillation of BMAL1. In addition, the disrupted circadian oscillations in the MYC-expressing cancer cells could be partially rescued by inhibiting expression of REV-ERBα.

Both higher REV-ERBα expression or lower BMAL1 expression are predictive of poor clinical outcomes for human neuroblastoma, as determined by patient survival data from The Children's Hospital of Philadelphia and the University of Cologne, Germany.

They compared gene expression from tumors of 740 patients (combined from two studies) to overall patient survival to arrive at these correlations. In addition, re-expression of BMAL1 in neuroblastoma cell lines suppresses their ability to replicate. MYC also profoundly alters the oscillations of glucose metabolism and perturbs the consumption of glutamine, both essential metabolic molecules for cells.

"We thought that some cancer cells' metabolites oscillate and some don't, but we had not tested it," Altman recalled. To address these questions, the researchers used an osteosarcoma cancer cell line to study the interaction of MYC and metabolism in cancer cells. When they increased MYC, glucose was taken up at a much greater rate in these cells.

"This led us to better understand how and why cancer cells efficiently hijack the cell's energetics machinery to be able to keep up rapid replication," Hsieh said. Knowing that cancer cells have a different metabolic profile, the team surmises that this can inform when to treat cancer, which is when normal cells are quiet. This will decrease toxicity, while increasing efficacy against the always-awake cancer cell.

"Our results demonstrate an unsuspected link between the cancer-causing abilities of some cells and abnormal circadian and metabolic rhythms, which we surmise to be advantageous for cancer," Dang said.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs